Resverlogix Corp.

Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors

    Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company")  announced  today that the Board of Directors has elected Arthur J. Higgins, CEO of  Bayer HealthCare and Chairman of the Bayer HealthCare Executive Committee,  to the Board effective February 1, 2010.

    Mr. Higgins joined Bayer in 2004 as Chairman of the Bayer HealthCare Executive Committee and in 2006 was named Chairman of the Board of Management of Bayer HealthCare. Mr. Higgins has played a key role in driving the success of Bayer HealthCare through a combination of strong organic growth and key acquisitions, including the (euro)17 billion acquisition of the German pharmaceutical company, Schering AG, in 2006.

    "Arthur Higgins' global leadership experience and exposure to numerous healthcare markets are just a few of the reasons that he is a valued addition to the Board," said Donald J. McCaffrey, President & CEO of Resverlogix. "As we progress through our Phase 2 clinical trials, we welcome Mr. Higgins' perspective as a strategist and R&D specialist."

    Mr. Higgins was born in Airdrie, Scotland. He studied at Scotland's Strathclyde University from 1974 to 1978, where he gained a Bachelor of Science degree in biochemistry.

    Mr. Higgins started his career in 1978 in England with Bristol-Myers. He subsequently worked for Sandoz (1979 to 1984) and Fisons (1984 to 1987) before moving to Abbott Laboratories in the USA (1987 to 2001), where he held  various positions of increasing responsibility in the international and  domestic divisions, including a two-year posting in Germany. He was appointed  President of the Pharmaceutical Products Division in Chicago, Illinois, USA, in 1998. In this position, he was in charge of Abbott's pharmaceuticals  business in the United States with responsibility for global pharmaceutical  research and development.

    In 2001, Mr. Higgins was appointed Chairman and CEO of Enzon Pharmaceuticals headquartered in Bridgewater, New Jersey, USA. In this function, he also served as Chairman of the Biotech Council of New Jersey and on the board of the U.S. National Pharmaceutical Council.

    Mr. Higgins represents Bayer in the Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA), and is also a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

    From May 2007 until December 2009, Mr. Higgins was President of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

    About Resverlogix Corp.  

    Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange . For further information please visit http://www.resverlogix.com.

    This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our  vision to be a leader in the research, development and commercialization of  novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts"  and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these  forward-looking statements. We can give no assurance that any of the events  or expectations will occur or be realized. By their nature, forward-looking  statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research  and development programs, clinical trial programs including possible delays  in patient recruitment, the regulatory approval process, competition,  securing and maintaining corporate alliances, market acceptance of the  Company's products, the availability of government and insurance  reimbursements for the Company's products, the strength of intellectual  property, financing capability, the potential dilutive effects of any  financing, reliance on subcontractors and key personnel and additional risk  factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at http://www.sedar.com. The forward-looking statements contained in this news  release are expressly qualified by this cautionary statement are  made as of the date hereof. The Company disclaims any intention and has no  obligation or responsibility, except as required by law, to update or revise  any forward-looking statements, whether as a result of new information,  future events or otherwise. The TSX Exchange does not accept responsibility  for the adequacy or accuracy of this news release.

    For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1(403)254-9252, Fax: +1(403)256-8495, Email: Theresa@resverlogix.com; US Investor Relations: Susan Noonan, Managing Partner, S.A. Noonan Communications, LLC, Phone: +1(212)966-3650, Email: susan@sanoonan.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
CONTACT:  For further information: Theresa Kennedy, VP,
CorporateCommunications, Resverlogix Corp., Phone: +1(403)254-9252,
Fax:+1(403)256-8495, Email: Theresa@resverlogix.com; US Investor
Relations:Susan Noonan, Managing Partner, S.A. Noonan Communications,
LLC, Phone:+1(212)966-3650, Email: susan@sanoonan.com



Weitere Meldungen: Resverlogix Corp.

Das könnte Sie auch interessieren: